Local delivery strategies in epilepsy; A focus on adenosine

Seizure

Volumn 20, Issue 5, 2011, Pages 376-382

  Van Dycke, Annelies ^a   Raedt, Robrecht ^a   Vonck, Kristl ^a   Boon, Paul ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Adenosine; Cell transplantation; Convection enhanced delivery; Epilepsy; Gene therapy; Intrathecal; Intraventricular; Liposome; Local delivery; Nanoparticles; Polymer; Pump; Stem cell

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADENOSINE; ADENOSINE DERIVATIVE; CARMUSTINE; ETHYLENE VINYL ACETATE COPOLYMER; GABAPENTIN; GALANIN; HERPESVIRUS VECTOR; LIPOSOME; NANOPARTICLE; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTRANSMITTER; NORADRENALIN; PARVOVIRUS VECTOR; PHENOBARBITAL; POLYMER; RETROVIRUS VECTOR; SEROTONIN; VALPROIC ACID;

ANTICONVULSANT ACTIVITY; BLOOD BRAIN BARRIER; BRAIN REGION; CATHETER; COLLOID; CONTROLLED RELEASE FORMULATION; CONVECTION ENHANCED DELIVERY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; EMBRYONIC STEM CELL; EPILEPSY; EPILEPTIC STATE; EX VIVO GENE TRANSFER; GLIOMA; HUMAN; IN VIVO GENE TRANSFER; MESENCHYMAL STEM CELL; MINIPUMP; NEURAL STEM CELL; NONHUMAN; OSMOTIC MINIPUMP; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TEMPORAL LOBE EPILEPSY; THERMODYNAMICS; VIRAL GENE DELIVERY SYSTEM;

ADENOSINE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; EPILEPSY; GENE THERAPY; HUMANS;

EID: 79955700531     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2011.03.003     Document Type: Review

References (105)

1. Panayiotopoulos CP. Principles of therapy in the epilepsies. In: Panayiotopoulos CP, editor. A clinical guide to epileptic syndromes and their treatment. Springer; 2007. p. 155-84.
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9. (Pubitemid 30075244)
3. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005;46:224-35. (Pubitemid 40194666)
4. Loscher W. Drug transporters in the epileptic brain. Epilepsia 2007;48(Suppl. 1):8-13. (Pubitemid 46280513)
5. Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 2003;16:197-201. (Pubitemid 36521207)
6. Oby E, Janigro D. The blood-brain barrier and epilepsy. Epilepsia 2006;47:1761-74. (Pubitemid 44730046)
7. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-8. (Pubitemid 36407173)
8. Volk HA, Burkhardt K, Potschka H, Chen J, Becker A, Loscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 2004;123:751-9. (Pubitemid 38045412)
9. Volk HA, Potschka H, Loscher W. Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res 2004;58:67-79. (Pubitemid 38447137)
10. Volk HA, Loscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 2005;128:1358-68. (Pubitemid 40826189)
11. Siegal T. Strategies for increasing drug delivery to the brain: lessons derived from treatment of brain tumors. In: Kobiler D, Lustig S, Shapira S, editors. Blood-brain barrier: drug delivery and brain pathology. Kluwer Academic/ Plenum Publishers; 2001. p. 251-72.
12. Bickel U. Targeting macromolecules to the central nervous system. In: Begley DJ, Bradbury MW, Kreuter J, editors. The blood-brain barrier and drug delivery to the CNS. Marcel Dekker; 2002. p. 171-204.
13. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection- enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;91:2076-80. (Pubitemid 24092045)
14. Cook AM,Mieure KD, Owen RD, Pesaturo AB, Hatton J. Intracerebroventricular administration of drugs. Pharmacotherapy 2009;29:832-45.
15. Fisher RS, Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs 2002;16:579-93.
16. Belverud S, Mogilner A, Schulder M. Intrathecal pumps. Neurotherapeutics 2008;5:114-22. (Pubitemid 350299303)
17. Brennan PM, Whittle IR. Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. Br J Neurosurg 2008;22:508-19.
18. Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med 2006;79:141-52.
19. Lin SH, Kleinberg LR. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 2008;8:343-59. (Pubitemid 351836283)
20. Wang PP, Frazier J, Brem H. Local drug delivery to the brain. Adv Drug Deliv Rev 2002;54:987-1013.
21. Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 2009;30:2302-18.
22. Bidros DS, Vogelbaum MA. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics 2009;6:539-46.
23. Hall WA. Convection-enhanced delivery: neurosurgical issues. Curr Drug Targets 2009;10:126-30.
24. Barbu E, Molnar E, Tsibouklis J, Gorecki DC. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv 2009;6:553-65.
25. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009;30:592-9.
26. Zhang L, Gu FX, Chan JM,Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008;83:761-9. (Pubitemid 351556021)
27. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 2008;3:133-49. (Pubitemid 352042401)
28. Crook JM, Kobayashi NR. Human stem cells for modeling neurological disorders: accelerating the drug discovery pipeline. J Cell Biochem 2008;105:1361-6.
29. Loscher W, Gernert M, Heinemann U. Cell and gene therapies in epilepsy - promising avenues or blind alleys? Trends Neurosci 2008;31:62-73.
30. Raedt R, Van Dycke A, Vonck K, Boon P. Cell therapy in models for temporal lobe epilepsy. Seizure 2007;16:565-78. (Pubitemid 47300155)
31. Sebe JY, Baraban SC. The promise of an interneuron-based cell therapy for epilepsy. Dev Neurobiol 2011;71:107-17.
32. Mayhall EA, Paffett-Lugassy N, Zon LI. The clinical potential of stem cells. Curr Opin Cell Biol 2004;16:713-20. (Pubitemid 39463124)
33. Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature 2006;441:1094-6. (Pubitemid 43990722)
34. Muller FJ, Snyder EY, Loring JF. Gene therapy: can neural stem cells deliver? Nat Rev Neurosci 2006;7:75-84.
35. Moirano J, Emborg ME. Nonhuman primate models for testing gene therapy for neurodegenerative disorders. In: Kaplitt MG, During MJ, editors. Gene therapy in the central nervous system: from bench to bedside. Elsevier; 2006. p. 109-19.
36. Suhr ST, Gage FH. Gene therapy for neurologic disease. Arch Neurol 1993;50:1252-68. (Pubitemid 23327781)
37. McCown TJ. The future of epilepsy treatment: focus on adeno-associated virus vector gene therapy. Drug News Perspect 2010;23:281-6.
38. Vezzani A. Gene therapy in epilepsy. Epilepsy Curr 2004;4:87-90.
39. Vezzani A. The promise of gene therapy for the treatment of epilepsy. Expert Rev Neurother 2007;7:1685-92. (Pubitemid 350260669)
40. Serralta A, Barcia JA, Ortiz P, Duran C, Hernandez ME, Alos M. Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model. Epilepsy Res 2006;70:15-26. (Pubitemid 43947512)
41. Barcia JA, Gallego JM. Intraventricular and intracerebral delivery of antiepileptic drugs in the kindling model. Neurotherapeutics 2009;6:337-43.
42. Boison D, Scheurer L, Tseng JL, Aebischer P, Mohler H. Seizure suppression in kindled rats by intraventricular grafting of an adenosine releasing synthetic polymer. Exp Neurol 1999;160:164-74.
43. Guttinger M, Fedele D, Koch P, Padrun V, Pralong WF, Brustle O, et al. Suppression of kindled seizures by paracrine adenosine release from stem cell-derived brain implants. Epilepsia 2005;46:1162-9. (Pubitemid 41647752)
44. Guttinger M, Padrun V, Pralong WF, Boison D. Seizure suppression and lack of adenosine A1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts. Exp Neurol 2005;193:53-64. (Pubitemid 40463267)
45. Huber A, Padrun V, Deglon N, Aebischer P, Mohler H, Boison D. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci USA 2001;98:7611-6. (Pubitemid 32567996)
46. Li T, Steinbeck JA, Lusardi T, Koch P, Lan JQ, Wilz A, et al. Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain 2007;130:1276-88. (Pubitemid 47355953)
47. Li T, Ren G, Kaplan DL, Boison D. Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis. Epilepsy Res 2009;84:238-41.
48. Ren G, Li T, Lan JQ, Wilz A, Simon RP, Boison D. Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control. Exp Neurol 2007;208:26-37. (Pubitemid 47600151)
49. Szybala C, Pritchard EM, Lusardi TA, Li T, Wilz A, Kaplan DL, et al. Antiepileptic effects of silk-polymer based adenosine release in kindled rats. Exp Neurol 2009;219:126-35.
50. Van Dycke A, Raedt R, Dauwe I, Sante T, Wyckhuys T, Meurs A, et al. Continuous local intrahippocampal delivery of adenosine reduces seizure frequency in rats with spontaneous seizures. Epilepsia 2010;51:1721-8.
51. Wilz A, Pritchard EM, Li T, Lan JQ, Kaplan DL, Boison D. Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials 2008;29:3609-16.
52. Ferencz I, Kokaia M, Elmer E, Keep M, Kokaia Z, Lindvall O. Suppression of kindling epileptogenesis in rats by intrahippocampal cholinergic grafts. Eur J Neurosci 1998;10:213-20. (Pubitemid 28325442)
53. Barcia JA, Castillo A, Gutierrez R, Gallego JM, Ortiz L, Hernandez ME. Continuous intra-amygdalar infusion of GABA in the amygdala kindling model of epilepsy in rat. Epilepsy Res 2004;58:19-26. (Pubitemid 38447132)
54. Gallego JM, Ortiz L, Gutierrez R, Barcia JA. Continuous bilateral infusion of GABA in the dorsomedian nucleus of the thalamus elevates the generalized seizure threshold in amygdala-kindled rats. Seizure 2009;18:537-40.
55. Gernert M, Thompson KW, Loscher W, Tobin AJ. Genetically engineered GABA-producing cells demonstrate anticonvulsant effects and long-term transgene expression when transplanted into the central piriform cortex of rats. Exp Neurol 2002;176:183-92. (Pubitemid 34762118)
56. Hattiangady B, Rao MS, Shetty AK. Grafting of striatal precursor cells into hippocampus shortly after status epilepticus restrains chronic temporal lobe epilepsy. Exp Neurol 2008;212:468-81.
57. Kokaia M, Aebischer P, Elmer E, Bengzon J, Kalen P, Kokaia Z, et al. Seizure suppression in kindling epilepsy by intracerebral implants of GABA- but not by noradrenaline-releasing polymer matrices. Exp Brain Res 1994;100:385-94. (Pubitemid 24281988)
58. Loscher W, Ebert U, Lehmann H, Rosenthal C, Nikkhah G. Seizure suppression in kindling epilepsy by grafts of fetal GABAergic neurons in rat substantia nigra. J Neurosci Res 1998;51:196-209. (Pubitemid 28073027)
59. Thompson K, Anantharam V, Behrstock S, Bongarzone E, Campagnoni A, Tobin AJ. Conditionally immortalized cell lines, engineered to produce and release GABA, modulate the development of behavioral seizures. Exp Neurol 2000;161:481-9. (Pubitemid 30137008)
60. Thompson K. Transplantation of GABA-producing cells for seizure control in models of temporal lobe epilepsy. Neurotherapeutics 2009;6:284-94.
61. Thompson KW, Suchomelova LM. Transplants of cells engineered to produce GABA suppress spontaneous seizures. Epilepsia 2004;45:4-12. (Pubitemid 38067239)
62. Thompson KW. Genetically engineered cells with regulatable GABA production can affect afterdischarges and behavioral seizures after transplantation into the dentate gyrus. Neuroscience 2005;133:1029-37. (Pubitemid 40814610)
63. Barry DI, Kikvadze I, Brundin P, Bolwig TG, Bjorklund A, Lindvall O. Grafted noradrenergic neurons suppress seizure development in kindling-induced epilepsy. Proc Natl Acad Sci USA 1987;84:8712-5. (Pubitemid 18033474)
64. Barry DI, Wanscher B, Kragh J, Bolwig TG, Kokaia M, Brundin P, et al. Grafts of fetal locus coeruleus neurons in rat amygdala-piriform cortex suppress seizure development in hippocampal kindling. Exp Neurol 1989;106:125-32. (Pubitemid 19279478)
65. Bengzon J, Brundin P, Kalen P, Kokaia M, Lindvall O. Host regulation of noradrenaline release from grafts of seizure-suppressant locus coeruleus neurons. Exp Neurol 1991;111:49-54.
66. Bortolotto ZA, Calderazzo L, Cavalheiro EA. Some evidence that intrahippocampal grafting of noradrenergic neurons suppresses spontaneous seizures in epileptic rats. Braz J Med Biol Res 1990;23:1267-9.
67. Buzsaki G, Ponomareff G, Bayardo F, Shaw T, Gage FH. Suppression and induction of epileptic activity by neuronal grafts. Proc Natl Acad Sci USA 1988;85:9327-30. (Pubitemid 19001889)
68. Kokaia M, Cenci MA, Elmer E, Nilsson OG, Kokaia Z, Bengzon J, et al. Seizure development and noradrenaline release in kindling epilepsy after noradrenergic reinnervation of the subcortically deafferented hippocampus by superior cervical ganglion or fetal locus coeruleus grafts. Exp Neurol 1994;130:351-61.
69. Lindvall O, Barry DI, Kikvadze I, Brundin P, Bolwig TG, Bjorklund A. Intracerebral grafting of fetal noradrenergic locus coeruleus neurons: evidence for seizure suppression in the kindling model of epilepsy. Prog Brain Res 1988;78:79-86. (Pubitemid 19023526)
70. Clough R, Statnick M, Maring-Smith M, Wang C, Eells J, Browning R, et al. Fetal raphe transplants reduce seizure severity in serotonin-depleted GEPRs. Neuroreport 1996;8:341-6. (Pubitemid 126785585)
71. Kanter-Schlifke I, Toft SA, Ledri M, Kuteeva E, Hokfelt T, Kokaia M. Galanin gene transfer curtails generalized seizures in kindled rats without altering hippocampal synaptic plasticity. Neuroscience 2007;150:984-92. (Pubitemid 350245561)
72. Lin EJ, Richichi C, Young D, Baer K, Vezzani A, During MJ. Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci 2003;18:2087-92. (Pubitemid 37372391)
73. McCown TJ. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol Ther 2006;14:63-8. (Pubitemid 43899490)
74. Boon P, Dauwe I, Van Dycke A, Meurs A, Wyckhuys T, Wadman W, et al. Local infusion of neuropeptide Y has anti-epileptic effects in fully kindled rats. Eur J Neurol 2009;16(Suppl. 3):141.
75. Noe F, Pool AH, Nissinen J, Gobbi M, Bland R, Rizzi M, et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008;131:1506-15. (Pubitemid 351806462)
76. Reibel S, Benmaamar R, Le BT, Larmet Y, Kalra SP, Marescaux C, et al. Neuropeptide Y delays hippocampal kindling in the rat. Hippocampus 2003;13:557-60. (Pubitemid 36958280)
77. Richichi C, Lin EJ, Stefanin D, Colella D, Ravizza T, Grignaschi G, et al. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 2004;24:3051-9. (Pubitemid 38405752)
78. Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM. Adenosine and brain function. Int Rev Neurobiol 2005;63:191-270. (Pubitemid 43631262)
79. Boison D. Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmacol Sci 2006;27:652-8. (Pubitemid 44738092)
80. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007;14:1315-23. (Pubitemid 46965261)
81. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52.
82. Benarroch EE. Adenosine and its receptors: multiple modulatory functions and potential therapeutic targets for neurologic disease. Neurology 2008;70:231-6.
83. Fredholm BB, Chen JF, Masino SA, Vaugeois JM. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 2005;45:385-412. (Pubitemid 40261811)
84. Boison D. Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist 2005;11:25-36. (Pubitemid 40223088)
85. Abdul-Ghani AS, Attwell PJ, Bradford HF. The protective effect of 2-chloroadenosine against the development of amygdala kindling and on amygdalakindled seizures. Eur J Pharmacol 1997;326:7-14. (Pubitemid 27205039)
86. Anschel DJ, Ortega EL, Kraus AC, Fisher RS. Focally injected adenosine prevents seizures in the rat. Exp Neurol 2004;190:544-7. (Pubitemid 39505008)
87. Franklin PH, Zhang G, Tripp ED, Murray TF. Adenosine A1 receptor activation mediates suppression of (-) bicuculline methiodide-induced seizures in rat prepiriform cortex. J Pharmacol Exp Ther 1989;251:1229-36. (Pubitemid 20024949)
88. Rosen JB, Berman RF. Differential effects of adenosine analogs on amygdala, hippocampus, and caudate nucleus kindled seizures. Epilepsia 1987;28: 658-66. (Pubitemid 18021804)
89. Zhang G, Franklin PH, Murray TF. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J Pharmacol Exp Ther 1993;264:1415-24. (Pubitemid 23318640)
90. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972;32:281-94.
91. McIntyre DC, Poulter MO, Gilby K. Kindling: some old and some new. Epilepsy Res 2002;50:79-92. (Pubitemid 34876589)
92. Racine R. Kindling: the first decade. Neurosurgery 1978;3:234-52.
93. Hellier JL, Patrylo PR, Buckmaster PS, Dudek FE. Recurrent spontaneous motor seizures after repeated low-dose systemic treatment with kainate: assessment of a rat model of temporal lobe epilepsy. Epilepsy Res 1998;31:73-84. (Pubitemid 28305406)
94. Nissinen J, Pitkanen A. Effect of antiepileptic drugs on spontaneous seizures in epileptic rats. Epilepsy Res 2007;73:181-91. (Pubitemid 46329332)
95. Boison D. Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies. Epilepsy Res 2009;85:131-41.
96. Fedele DE, Koch P, Scheurer L, Simpson EM, Mohler H, Brustle O, et al. Engineering embryonic stem cell derived glia for adenosine delivery. Neurosci Lett 2004;370:160-5. (Pubitemid 39370871)
97. Boison D. Engineered adenosine-releasing cells for epilepsy therapy: human mesenchymal stem cells and human embryonic stem cells. Neurotherapeutics 2009;6:278-83.
98. Boison D, Scheurer L, Zumsteg V, Rulicke T, Litynski P, Fowler B, et al. Neonatal hepatic steatosis by disruption of the adenosine kinase gene. Proc Natl Acad Sci USA 2002;99:6985-90. (Pubitemid 34526244)
99. Van Dycke A, Verstraete A, Pil K, Raedt R, Vonck K, Boison D, et al. Quantitative analysis of adenosine using liquid chromatography/atmospheric pressure chemical ionization - tandem mass spectrometry (LC/APCI-MS/MS). J Chromatogr B Anal Technol Biomed Life Sci 2010;878:1493-8.
100. Van Dycke A, Raedt R, Verstraete A, Theofilas P, Wadman W, Vonck K, et al. Astrocytes derived from fetal neural progenitor cells as a novel source for therapeutic adenosine delivery. Seizure 2010;19:390-6.
101. Raedt R, Van Dycke A, Waeytens A, Wyckhuys T, Vonck K, Wadman W, et al. Unconditioned adult-derived neurosphere cells mainly differentiate towards astrocytes upon transplantation in sclerotic rat hippocampus. Epilepsy Res 2009;87:148-59.
102. Turner DA, Shetty AK. Clinical prospects for neural grafting therapy for hippocampal lesions and epilepsy. Neurosurgery 2003;52:632-44. (Pubitemid 36259013)
103. Zaman V, Turner DA, Shetty AK. Prolonged postlesion transplantation delay adversely influences survival of both homotopic and heterotopic fetal hippocampal cell grafts in kainate-lesioned CA3 region of adult hippocampus. Cell Transplant 2001;10:41-52. (Pubitemid 32247069)
104. Hattiangady B, Rao MS, Zaman V, Shetty AK. Incorporation of embryonic CA3 cell grafts into the adult hippocampus at 4-months after injury: effects of combined neurotrophic supplementation and caspase inhibition. Neuroscience 2006;139:1369-83.
105. Shon YM, Chang SY, Tye SJ, Kimble CJ, Bennet KE, Blaha CD, et al. Comonitoring of adenosine and dopamine using the wireless instantaneous neurotransmitter concentration system: proof of principle. J Neurosurg 2010;112:539-48.